Intellia Therapeutics (NTLA) Announces Fiscal Q4 and Full Year 2025 Financial Results

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is one of the top gene therapy stocks to buy according to hedge funds. Intellia Therapeutics, Inc. (NASDAQ:NTLA) announced its fiscal Q4 and full year 2025 financial results on February 26, reporting cash, cash equivalents, and marketable securities of $605.1 million as of December 31, 2025, compared to $861.7 million in the prior year period. The company expects its cash, cash equivalents, and marketable securities as of December 31, 2025, to fund operations into the second half of 2027, as well as through lonvo-z’s anticipated U.S. commercial launch for HAE.

Management further reported that the collaboration revenue for the quarter was $23.0 million, compared to $12.9 million for the prior year period. The increase was attributed to the recognition of $9.0 million in revenue related to the termination of the license and collaboration agreement with SparingVision SAS, along with an increase in cost reimbursements related to the company’s collaboration with Regeneron. Research and development expenses for the quarter came up to $88.7 million, compared to $116.9 million for the prior year period.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a clinical-stage genome editing company involved in the development of curative therapeutics using the CRISPR/Cas9 system.

While we acknowledge the potential of NTLA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.